May 6, 2026 . Report Back from SGO: What’s New in Uterine Cancer?
Pamela T. Soliman, MD, MPH Professor Department of Gynecologic Oncology and Reproductive Medicine
MD
Anderson Cancer Center
SGO Annual Meeting 2026
Highlights in Endometrial Cancer
• Novel Therapies
• Abemaciclib/letrozole
• Trastuzumab pamirtecan (T-pam)
• Mocertutag rezetecan (Mo-Rez)
• Comprehensive profiling for ADC targets
• Long-term outcomes
• DESTINY-PanTumor02, Part 1 final analysis
• Ruby trial 4-year survival
• Healthy equity
• Sister study
Highlights in Endometrial Cancer
• Multiple ongoing clinical trials that are going to impact clinical practice
• With novel therapies we have to learn to manage drugs with new side effect profiles
• Sequencing of therapy is going to be our next priority as more drugs become commercially available
• Long term follow up is important to confirm early findings and help with counselling patients
• Novel ways to support patients through treatment can also havea an impact on outcomes